ArticlePloS one2013
Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 41 citations in OpenAlex.
- The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling.Frontiers in oncology · 2022Article
- Article
- The Pathophysiological Significance of Fibulin-3.Biomolecules · 2020Review
- The expression of Fibulin-3 in ovarian cancer and its relationship with prognosis.Translational cancer research · 2020Article
- Identification of genes associated with gastric cancer survival and construction of a nomogram to improve risk stratification for patients with gastric cancer.Oncology letters · 2020Article
- Dual antivascular function of human fibulin-3 variant, a potential new drug discovery strategy for glioblastoma.Cancer science · 2020Article
- EFEMP1 Overexpression Contributes to Neovascularization in Age-Related Macular Degeneration.Frontiers in pharmacology · 2020Article
- EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma.BioMed research international · 2020Article
- Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B).Cancer medicine · 2019Article
- Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.BMC cancer · 2018Article
- Fibulin-3 knockdown inhibits cervical cancer cell growth and metastasis in vitro and in vivo.Scientific reports · 2018Article
- The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion.Oncotarget · 2018Article
- Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- A map of human circular RNAs in clinically relevant tissues.Journal of molecular medicine (Berlin, Germany) · 2017Article
- Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors.Oncology letters · 2017Article
- Fibulin-3 promotes muscle-invasive bladder cancer.Oncogene · 2017Article
- Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment.Oncogene · 2017Article
- Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/β-catenin signaling pathway.Scientific reports · 2017Article
- Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.Breast cancer research and treatment · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was to explore the role of EFEMP1 in ovarian tumor progression and its relationship with prognosis of ovarian carcinoma.
methodsEFEMP1 mRNA and protein expressions in normal ovarian tissue, ovarian tumor, high invasive subclones and low invasive subclones were evaluated by immunohistochemistry and real time RT-PCR. Serum EFEMP1 levels in patients with ovarian tumor were measured by ELISA assay. To assess the angiogenic properties of EFEMP1, VEGF and tumor microvessel density were analyzed in ovarian carcinoma by immunohistochemistry.
resultsEFEMP1 expression was up-regulated in ovarian carcinoma, positively correlated with MVD and VEGF, and its overexpression and high serum levels were significantly associated with high stage, low differentiation, lymph node metastasis and poor prognosis of ovarian cancer. EFEMP1 expression was also found to be over-expressed in the highly invasive subclones compared with the low invasive subclones.
conclusionEFEMP1 is a newly identified gene over-expressed in ovarian cancer, associated with poor clinicopathologic features and promotes angiogenesis. This study shows that EFEMP1 may serve as a new prognostic factor and a therapeutic target for patients with ovarian cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.